The p300/CBP inhibitor company

We are developing inobrodib, a new drug to benefit people with cancer

  • 50+

    Epigenetic-related targets

    investigated over time by the CellCentric team

  • 1

    Drug prioritised, advanced

    Inobrodib in the clinic, to treat specific cancers

Inobrodib is a first-in-class oral anti-cancer drug that targets twin tumour drivers, p300/CBP. It is a small molecule, formulated as a capsule taken orally, in Phase I/II clinical trials.

p300/CBP are twin (paralogue) acetyl transferases and gene activating proteins that are known to play an important role in the progression of certain cancers.

Inobrodib is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer.

CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late-stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.

Tweets by @CellCentric

Follow us

As we develop our new cancer drug, inobrodib, we listen to patients. Having an oral product that can be taken at home, reducing time spent at hospital, is a big differentiator. pic.twitter.com/DBQfrnrzW9

CellCentric presenting at #ASH22. Exciting Phase I data treating RR multiple myeloma, and other haems. Inobrodib: small molecule p300/CBP inhibitor. cellcentric.com/updates/press-… pic.twitter.com/FW3mgZqwx7

Kris and Neil at #PCFRetreat22 Carlsbad CA, meeting our international clinical collaborators. Inobrodib being trialled to treat mCRPC. pic.twitter.com/8KSTk2MI8v